Recurrent respiratory papillomatosis: update 2018.

Area of Science:

• Otolaryngology
• Oncology
• Immunology

Background:

• Recurrent respiratory papillomatosis (RRP) is the most common and costly benign airway neoplasm in the US.
• RRP poses risks of airway obstruction and malignant conversion.
• Understanding RRP's pathophysiology, epidemiology, and natural history is crucial.

Purpose of the Study:

• To review recent advancements in RRP understanding and treatment.
• To highlight progress in scientific knowledge over the past 1-2 years.
• To discuss new frontiers in managing this challenging disease.

Main Methods:

• Review of recent scientific literature on RRP.
• Analysis of findings related to RRP pathophysiology, epidemiology, and treatment.
• Synthesis of data on novel therapeutic approaches and preventive strategies.

Main Results:

• Voice-related quality of life is significantly impacted.
• Adult-onset RRP may correlate with laryngopharyngeal reflux and HSV-2.
• Vaccination programs show declining RRP incidence and can be therapeutic.
• Novel treatments like bevacizumab and DNA vaccines show promise.
• Immune markers like PD-1/PD-L1 are implicated in RRP pathogenesis.

Conclusions:

• RRP incidence is declining but remains a significant healthcare burden.
• New treatment avenues are emerging, especially for severe RRP.
• Continued research is vital for RRP prevention and effective patient management.